New hope for ALS patients denied other trials
Disease control
AVAILABLE
This program provides the experimental drug SPG302 to adults with ALS who cannot join other clinical trials. It aims to assess the drug's safety and whether it helps slow the disease. Participants must have some remaining lung function and be on stable ALS medications if currentl…
Sponsor: Spinogenix • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC